Mutagenicity studies of muroctasin.
A synthetic muramyl dipeptide derivative N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), muroctasin) was studied for mutagenicity using the Ames method, in vitro cytogenetics and micronucleus test. MDP-Lys(L18) had no mutagenic effect on S. typhimurium (TA1535, TA1537, TA1538, TA98 and TA100) or E. coli (WP2 uvrA) in the reverse mutation assay. In the cytogenetic study, MDP-Lys(L18) had no effect on the chromosomes of the Chinese hamster cells at cytotoxic doses. Single subcutaneous treatment of MDP-Lys(L18) at dose levels of 3.5, 35 or 350 mg/kg in the mouse micronucleus test did not increase the incidence of micronucleated polychromatic erythrocytes. These results show that MDP-Lys(L18) has no demonstrable mutagenic potential.
Shimada
H
H
Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.
Hattori
C
C
Sato
T
T
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000633:toxicity; D000276:Adjuvants, Immunologic / Q000633:toxicity*; D000818:Animals; D002460:Cell Line; D002869:Chromosome Aberrations; D004926:Escherichia coli / Q000235:genetics; D008297:Male; D051379:Mice; D015162:Micronucleus Tests; D009152:Mutagenicity Tests; D009153:Mutagens; D012486:Salmonella typhimurium / Q000235:genetics
D000276:Adjuvants, Immunologic; D009153:Mutagens; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036866:romurtide